Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
Autor: | Kiattanaphon A; Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand., Vipsoongnern Y; National blood centre, The Thai Red Cross Society, Bangkok, Thailand., Kunthalert D; Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand., Sistayanarain A; Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand. sisaya@rocketmail.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Molecular biology reports [Mol Biol Rep] 2022 Oct; Vol. 49 (10), pp. 9437-9443. Date of Electronic Publication: 2022 Aug 24. |
DOI: | 10.1007/s11033-022-07803-5 |
Abstrakt: | Background: The hepatitis C virus (HCV) is a major cause of illness around the world. HCV genotype 3a is the most prevalent genotype in Thailand. Direct-acting antiviral (DAA) drugs are available for treatment, and these drugs target the NS3, NS5A, and NS5b proteins of HCV. However, HCV variants that are resistant to NS3 protease inhibitors have been found during treatment. This resistance can be naturally occurring or in response to treatment. The purpose of this study is to analyze the codon positions of the main mutation of the partial NS3 gene region of HCV genotype 3a. Methods: In order to detect mutations and confirm the genotype of HCV genotype 3a, the nucleotide sequencing and amino acid portion of NS3 were analyzed. Results: Twenty-six samples were successfully sequenced and clustered within two sub-clades defined as 3a-1 and 3a-2. Through amino acid mutation analysis, the variations were detected at codon positions 122 (3.8%), 132 (84.6%), 168 (100%), 170 (92.3%), 174 (100%), and 175 (100%). Conclusions: In conclusion, mutations at positions 168, 170, 174, and 175 of the NS3 region are common within the HCV genotype 3a. This information should be useful in the development of effective anti-viral drugs that can successfully treat HCV infection. (© 2022. The Author(s), under exclusive licence to Springer Nature B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |